Crossmark

Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers

Crossref DOI link: https://doi.org/10.1038/nbt.3199

Published Online: 2015-04-06

Published Print: 2015-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hilton, Isaac B https://orcid.org/0000-0002-3064-8532
D'Ippolito, Anthony M

Vockley, Christopher M

Thakore, Pratiksha I

Crawford, Gregory E

Reddy, Timothy E https://orcid.org/0000-0002-7629-061X
Gersbach, Charles A
License Information

Text and Data Mining valid from 2015-04-06
More Information

Article History

Received: 23 December 2014

Accepted: 16 March 2015

First Online: 6 April 2015

Competing interests

: C.A.G., I.B.H. and P.I.T. have filed patent applications related to genome engineering technologies. C.A.G. is a scientific advisor to Editas Medicine, a company engaged in therapeutic development of genome engineering technologies.